clinical trial · NCT07318688
Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain
Hope Medicine (Nanjing) Co., Ltd·phase3·not yet recruiting·n = 540
EndometriosisHMI-115Placebo
brief summary
A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension
started
Mar 1, 2026
primary completion
Mar 1, 2028
completion
Sep 1, 2028
last updated
Jan 6, 2026
official title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 24-Week Treatment Period and a 28-Week Extension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol